ABCDEFGHIJKLMNOPQRSTUVWXYZAA
1
TitleFirst NameLast NameDeptHEISummary of Research InterestsWebpageEmail
2
DrJimAngSchool of Engineering and Digital ArtsKentDigital health, including design and develop new technologies which can provide treatment and (self-)management of health conditions, through effective prevention, early intervention, personalised treatment and continuous monitoring.https://www.kent.ac.uk/engineering-digital-arts/people/622/ang-chee-siang--jimc.s.ang@kent.ac.uk
3
ProfMaxBachmannNorwich Medical SchoolUEAInnovation, integration and evaluation of health care for HIV/AIDS, tuberculosis, respiratory disease, diabetes, hypertension, depression, cancer, and other long term conditionshttps://people.uea.ac.uk/m_bachmannm.bachmann@uea.ac.uk
4
DrYongping BaoNorwich Medical SchoolUEAMechanisms of phytochemicals in cancer prevention; Interactions between isothiocyanates and selenium in selenoprotein gene expression.; Bioactivity of nanoencapsulated phytochemicals.https://people.uea.ac.uk/y_baoy.bao@uea.ac.uk
5
DrRobBarkerSchool of Physical SciencesKentBio-engineering and sensing, including: (a) Wearable continuous health monitoring (including body-worn blood monitoring) and real-time responsive treatment. (b) Development of non-invasive imaging technologies for rapid diagnosis. (c) Joint lubrication related to musculoskeletal issues. (d) Low-cost technologies reducing inequalities.https://www.kent.ac.uk/physical-sciences/people/459/barker-robertr.barker@kent.ac.uk
6
DrIanBealesNorwich Medical SchoolUEAbasic and translational science as well as clinical diagnostic and interventional studies in gastrointestinal cancers, most specifically oesophageal and colorectal cancers. The specific focus has been on understanding the links between endocrine and inflammatory pathways and the pathogenesis of cancer.https://people.uea.ac.uk/i_bealesi.beales@uea.ac.uk
7
DrAndrewBeekmanSchool of PharmacyUEAThe protein-protein interactions which control apoptosis in cancer; Protein interactions in immune checkpoints; Protein-protein interactions in telomerase to discover a new paradigm to trigger senescence in cancerhttps://people.uea.ac.uk/a_beekmanA.Beekman@uea.ac.uk
8
DrNaiara BerazaQuadram InstituteNRPDefining the mechanisms underpinning the gut-microbiome-liver axis communication during the initiation and progression of chronic disease, with a view to translate our findings to the clinical practice to treat liver disease and prevent cancer development.https://quadram.ac.uk/naiara-beraza/naiara.beraza@quadram.ac.uk
9
DrLindaBirtSchool of Health SciencesUEAThe experience of living with chronic illness, including the impact of biographical disruption; the competing responsibilities of informal caregiving; public attitudes and beliefs about cancer screening and help-seeking for cancer symptoms.https://people.uea.ac.uk/linda_birtlinda.birt@uea.ac.uk
10
DrTharin BlumenscheinSchool of Natural SciencesUEAUnderstanding protein structures and dynamics, and their role in protein interactions and function. In collaboration with other groups, we looked at three different cell signalling processes that are involved in cancer and apoptosis.https://people.uea.ac.uk/t_blumenscheint.Blumenschein@uea.ac.uk
11
DrStellaBolakiSchool of EnglishKentNarratives of illness and disability https://www.kent.ac.uk/english/people/79/www.kent.ac.uk/english/people/79/bolaki-stellas.bolaki@kent.ac.uk
12
ProfKristianBowlesNorwich Medical SchoolUEAHaematologist, and part of the Rushworth labhttps://people.uea.ac.uk/k_bowlesk.bowles@uea.ac.uk
13
DrDanielBrewerNorwich Medical SchoolUEAApplying and developing novel analytic techniques to large-scale ‘omic datasets from human tumour samples to answer clinically relevant questions in translational cancer research. https://people.uea.ac.uk/d_brewerd.brewer@uea.ac.uk
14
DrGregBrookeSchool of Life SciencesEssexTo improve treatment options and survival rates for cancer patients. My group is characterising factors that drive therapy resistance and identifying novel therapeutic targets.https://www.essex.ac.uk/people/brook66801/greg-brookegbrooke@essex.ac.uk
15
DrDonnieCameronNorwich Medical SchoolUEAComparison of different diffusion MRI methods for identifying, localising, and grading prostate cancer lesions; Correction of diffusion MRI distortion to improve prostate cancer localisation and specificity of diffusion MRI measures; Development of novel MRI methods for predicting ovarian cancer; Imaging of magnetic nanoparticles for cancer theranostics.https://people.uea.ac.uk/donnie_cameronDonnie.Cameron@uea.ac.uk
16
DrAndrewChantrySchool of Biological SciencesUEAA translational and drug discovery focus, and has projects aimed at developing novel therapeutic strategies targeting abnormal TGFb activity in cancer metastasis, leukaemia, osteoarthritis, and fibrotic disease. https://people.uea.ac.uk/a_chantrya.chantry@uea.ac.uk
17
DrYiminChaoSchool of ChemistryUEAThe development of nanoscale therapeutic agents that can be employed to provide a safer, time efficient, more direct route to identification, diagnosis and treatment of cancer as well as a whole host of other diseases. https://people.uea.ac.uk/y_chaoY.Chao@uea.ac.uk
18
DrJeremyClarkNorwich Medical SchoolUEAThe development and clinical implementation of diagnostic and prognostic tests for prostate cancer.https://people.uea.ac.uk/jeremy_clarkJeremy.Clark@uea.ac.uk
19
ProfColinCooperNorwich Medical SchoolUEACancer geneticshttps://people.uea.ac.uk/colin_coopercolin.cooper@uea.ac.uk
20
DrPaulCrichtonNorwich Medical SchoolUEAThe molecular and bioenergetic processes that occur in mitochondria and how they relate to our health. Membrane proteins are fundamental to mitochondrial energy transduction and uncoupling proteins (UCP1-5), in particular, are a current research focus of mine. My research aims to resolve the molecular and structural mechanisms that underlie UCP activity and regulation and, importantly, the function that these unusual proteins may play in pathophysiology and prevention of disease.https://people.uea.ac.uk/p_crichtonp.crichton@uea.ac.uk
21
ProfTamasDalmaySchool of Biological SciencesUEAPrimary interests in RNA silencing. Our research uses both plant and animal systems (Arabidopsis, tomato, mammals, chicken, etc.). The major theme in our laboratory is the role of microRNAs in various biological processes.https://people.uea.ac.uk/t_dalmayt.dalmay@uea.ac.uk
22
Dr JohnDickinsonSchool of Sport and Exercise SciencesKentLung function deteriorates as we age and the incidence of COPD. I am interested in investigations in maintaining respiratory health through the lifespan. This could involve investigating the interaction between exercise, environment and life style on lung health and changes in breathing patterns.https://www.kent.ac.uk/sport-sciences/people/333/www.kent.ac.uk/sport-sciences/people/333/dickinson-johnj.w.dickinson@kent.ac.uk
23
ProfDylanEdwardsNorwich Medical SchoolUEAThe functions of the human “degradome” – the repertoire of proteases and their inhibitors that cells and tissues use during tissue remodelling processes in development, tissue repair and disease states. A major focus of the work of the laboratory is on cancer, where we are studying proteases to identify novel diagnostic markers and therapeutic targets, and to identify the cellular and molecular mechanisms of extracellular proteases.https://people.uea.ac.uk/dylan_edwardsdylan.edwards@uea.ac.uk
24
DrPeterEllisSchool of BiosciencesKentMolecular genetics and reproduction, including DNA damage repair in reproduction and cancerhttps://www.kent.ac.uk/biosciences/people/1036/ellis-peterp.j.i.ellis@kent.ac.uk
25
DrBenjaminEvansNorwich Medical SchoolUEAUnderstanding which mechanisms bacteria are using to become resistant to antibiotics, and how these are evolving and being transferred in bacterial populations. An example of current work is investigating the effect of non-antibiotic drugs, such as cancer chemotherapies, on promoting antibiotic resistance. https://people.uea.ac.uk/benjamin_evansBenjamin.Evans@uea.ac.uk
26
DrMarinaEzcurra School of BiosciencesKentThe biology of ageing: how ageing and age-related diseases can be the result of run-on of wildtype gene function rather than stochastic molecular damage. https://www.kent.ac.uk/biosciences/people/2081/www.kent.ac.uk/biosciences/people/2081/ezcurra-marinam.ezcurra@kent.ac.uk
27
DrMoragFarquharSchool of Health SciencesUEABreathlessness in advanced disease, palliative care, informal carers, older people, and methodology – particularly the development and testing of interventions and mixed methods. https://people.uea.ac.uk/m_farquharm.farquhar@uea.ac.uk
28
DrTimFentonSchool of BiosciencesKentHuman papillomavirus (HPV)-driven carcinogenesis as a paradigm for understanding tumour development.https://www.kent.ac.uk/biosciences/people/1179/fenton-timt.fenton@kent.ac.uk
29
ProfNelson FernándezFernándezEssexCell-surface organization of immunoreceptors encoded by the Major Histocompatibility Complex (MHC), including role of CD74, MHC and tumour progression.https://www.essex.ac.uk/people/ferna53305/nelson-fernandeznelson@essex.ac.uk
30
ProfLindsayForbesCentre for Health Services StudiesKentDesign and evaluation of primary care services, and systems to build evidence of what works to improve the health of the public. Previously researched pathways to care in cancer and led the evaluation of a unique health professional-delivered intervention to promote early presentation of breast cancer.https://www.kent.ac.uk/chss/staff/research/forbes.htmlL.Forbes@kent.ac.uk
31
ProfRic FordhamNorwich Medical SchoolUEAThe development of priority setting techniques in complex decision making environments and he has adapted these for appropriate use in the practice of public healthhttps://people.uea.ac.uk/r_fordhamr.fordham@uea.ac.uk
32
ProfArasuGanesanSchool of PharmacyUEASmall molecule drug discovery and development. We apply the techniques of chemical biology and medicinal chemistry to target validation and the discovery and optimization of anticancer and antimicrobial agents.https://people.uea.ac.uk/a_ganesanA.Ganesan@uea.ac.uk
33
ProfMichelleGarrettSchool of BiosciencesKentUnderstanding the molecular and cellular effects of these and other functionally related drugs on the cancer cell. This research is being done using molecular and genetic technologies, including genome wide screening and high throughput cellular analysis.https://www.kent.ac.uk/biosciences/people/1185/garrett-michellem.d.garrett@kent.ac.uk
34
DrJelenaGavrilovicSchool of Biological SciencesUEACell-cell and cell-matrix interactions in skin health and disease, with an emphasis on inflammation, diabetes and melanomahttps://people.uea.ac.uk/j_gavrilovicj.gavrilovic@uea.ac.uk
35
Dr BenjaminGoultSchool of BiosciencesKentThe use of biophysical techniques to understand the structure and function of proteins that are involved in the process of Cell-extracellular matrix (ECM) adhesion. Such adhesion proteins are increasingly recognised as potential targets for therapeutic intervention in a range of pathologies including immune and vascular disorders, blood clotting, skin blistering, wound healing and cancer.https://www.kent.ac.uk/biosciences/people/1287/goult-benb.t.goult@kent.ac.uk
36
DrDarrellGreenNorwich Medical SchoolUEAGenetics, cell and molecular biology with next generation sequencing and bioinformatics to study the role of microRNAs in various biological processes. A major theme of research is sarcoma or bone and soft tissue tumours. https://people.uea.ac.uk/d_greend.green@uea.ac.uk
37
DrChristopherGreenhamSchool of Computing SciencesUEAThe development of techniques from statistical physics applied to age-dependent branching processes, including (quantum) field theoretic methods, applications to cell populations and mutation processes, combinatorial approaches to counting and representing genomic rearrangement processes, cancer and viral evolutionary processes. https://people.uea.ac.uk/c_greenmanc.greenman@uea.ac.uk
38
DrValeriiaHaberlandNorwich Medical SchoolUEACurrent project focuses on identifying prostate cancer sub-types with support from the Prostate Cancer Research Center. My current research interests lie in unsupervised machine learning algorithms for sub-type classification using RNA Seq data.https://people.uea.ac.uk/v_haberlandv.haberland@uea.ac.uk
39
DrWilfriedHaertyEarlham InstitueNRPCharacterising functional non-coding sequences and the evolutionary constraints acting on these elements across many species with a strong focus on mammalian genomes. Another significant part of my research involves the identification and characterisation of functional long non-coding RNAs in humans. I use comparative genomics approaches to quantify the action of selection acting on non-coding elements, with a strong focus on the patterns of sequence variation among populations.https://www.earlham.ac.uk/wilfried-haertywilfried.haerty@earlham.ac.uk
40
ProfRuthHancockNorwich Medical SchoolUEAEconomic, health and social policy implications of individual and population ageing with a particular focus on financial provision for later life and provision for long-term care needs.https://people.uea.ac.uk/r_hancockr.hancock@uea.ac.uk
41
DrSarahHansonSchool of Health SciencesUEAWork with marginalized groups (particularly women) to develop behavioral interventions to improve health literacy surrounding cancer to improve health behaviours, increase screening uptake, and develop early symptom awareness for earlier diagnosis.https://people.uea.ac.uk/s_hansonS.Hanson@uea.ac.uk
42
DrWendyHardemanSchool of Health SciencesUEAThe development and (trial) evaluation of behaviour change interventions to prevent and manage long-term conditions, in particular the promotion of physical activity and supporting medication taking.https://people.uea.ac.uk/w_hardemanW.Hardeman@uea.ac.uk
43
ProfNicoleHorwoodNorwich Medical SchoolUEAThe loss or gain of bone mass during disease, and the clinical treatment of bone cancers and metastases, inflammatory arthritis, osteoporosis, and periodontitis.https://people.uea.ac.uk/n_horwoodn.horwood@uea.ac.uk
44
DrRachelHurstNorwich Medical SchoolUEAA member of the Cancer Genetics team in the School of Biological Sciences and Norwich Medical School working with Professor Colin Cooper, Dr Jeremy Clark and colleagues on prostate cancer biomarkers.https://people.uea.ac.uk/r_hurst1R.Hurst1@uea.ac.uk
45
ProfBarbaraJenningsNorwich Medical SchoolUEAMolecular genetic medicine and the identification of predictive markers for cancer patients.https://people.uea.ac.uk/b_jenningsb.jennings@uea.ac.uk
46
ProfGlynJohnsonNorwich Medical SchoolUEADeveloping quantitative techniques that allow the resolution of diagnostic problems using MRI, particularly in relation to cancer.https://people.uea.ac.uk/glyn_johnson?_ga=2.243431237.133174987.1613128107-422142803.1604490904glyn.johnson@uea.ac.uk
47
ProfNathalieJugeQuadram InstituteNRPExamining how bacteria interact with mucins and their associated glycans at the mucosal surface, how mucus-associated bacteria communicate with the host and respond to changes in the physiological status of the host. Importantly, several conditions including inflammatory bowel disease (IBD) and colorectal cancer (CRC) are associated with alterations in mucus-associated bacteria and mucin glycosylationhttps://quadram.ac.uk/people/nathalie-juge/nathalie.juge@quadram.ac.uk
48
DrNeilKadSchool of BiosciencesKentHow the enzymes involved in DNA repair interact with one another and with their DNA substrate; how myosin's function is coupled to load, and also how myosin's function is related to its structure; using advanced technologies for probing single molecules, such as the use of nanoprobes in collaboration with the Rutherford Appleton Labs in Harwell.https://www.kent.ac.uk/biosciences/people/1303/kad-neiln.kad@kent.ac.uk
49
DrElenaKlenovaSchool of Life SciencesEssexRegulation of transcription and molecular mechanisms of tumourigenesis.https://www.essex.ac.uk/people/kleno10903/elena-klenovaklenovae@essex.ac.uk
50
DrTamás KorcsmárosEarlham InstitueNRPExperimental approaches to predict, analyse and validate host-microbe interactions in the gut, especially in relation to the regulation of autophagy by microbes and upon disease conditions such as inflammatory bowel disease and cancer.https://www.earlham.ac.uk/tamas-korcsmarosTamas.Korcsmaros@earlham.ac.uk
51
DrRianneLordSchool of ChemistryUEAThe synthesis and design of new metal-based therapeutics, working on compound modification and structure activity relationships. She is conducting in vitro analysis of all new compounds against a range of cancerous and normal cell lines, including assays on cellular interactions, uptake and compound speciation in physiological conditions. Her recent work has highlighted several classes of metal-based compounds which have high activity and cancer cell selectivity against colorectal cancer and lung cancer, and she is currently working on understanding the compounds’ modes of action within these cancers.https://people.uea.ac.uk/r_lordr.lord@uea.ac.uk
52
DrIainMacaulayEarlham InstitueNRPOur group develops tools to analyse the genomes, epigenomes and transcriptomes of individual cells, focusing especially on multi-omics approaches, where multiple aspects of cellular omics can be profiled in parallel. We are particularly interested in the application of these techniques to understand alternative splicing in normal cell development and disease, including the consequences of splicing mutations and fusion transcripts in cancer.https://www.earlham.ac.uk/iain-macaulayiain.macaulay@earlham.ac.uk
53
DrMariaMarinSchool of ChemistryUEAThe development of fluorescent ratiometric nanosensors for the quantification of intracellular analytes involved in disease states including cancer.https://people.uea.ac.uk/m_marin-altabam.marin-altaba@uea.ac.uk
54
DrSusanMatthewsSchool of PharmacyUEAThe interface between chemistry and biology and particularly on the use of supramolecular systems for drug and gene delivery and in novel antibacterial and anticancer treatments.https://people.uea.ac.uk/susan_matthewsSusan.Matthews@uea.ac.uk
55
DrMetodiMetodievSchool of Life SciencesEssexTranslational research; enabling personalized cancer therapy by proteogenomics: we combine computational data analysis with proteomics experiments conducted in the lab to identify and validate new diagnostic biomarkers and drug target candidates. Basic research; molecular mechanisms of signal transduction in the context of cancer, including CRISPR/Cas9 technique to edit candidate genes in the genome of human cell lines and study the effects of mutations found in large NGS datasets. https://www.essex.ac.uk/people/metod84401/metodi-metodievmmetod@essex.ac.uk
56
ProfMartinMichaelisSchool of BiosciencesKentThe identification and investigation of drugs and their mechanisms of action. The primary interest lies on acquired drug resistance in cancer. In collaboration with Professor Jindrich Cinatl (Goethe-University, Frankfurt am Main), he manages and develops the Resistant Cancer Cell Line (RCCL) Collection a unique collection of >1,300 cancer cell lines with acquired resistance to anti-cancer drugs.https://www.kent.ac.uk/biosciences/people/648/michaelis-martinm.michaelis@kent.ac.uk
57
ProfSabineMichalowskiSchool of LawEssexEnd-of-life decision-making, in particular the controversial issue of assisted dying. She is currently exploring the human rights implications of the partial legalisation of assisted dying.https://www.essex.ac.uk/people/micha31307/sabine-michalowskismichal@essex.ac.uk
58
ProfMetteMogensenSchool of Biological SciencesUEAMicrotubules and the centrosome and their roles in epithelial differentiation, remodelling and migration in health and cancer.https://people.uea.ac.uk/m_mogensenM.Mogensen@uea.ac.uk
59
AndreaMohrSchool of Life SciencesEssexCellular crosstalk in the tumour microenvironment leading to metastasis formation. I am especially interested in the role of mesenchymal stem cells (MSCs) in this process.https://www.essex.ac.uk/people/mohra32204/andrea-mohramohr@essex.ac.uk
60
DrDavidMonkSchool of Biological SciencesUEAUnderstanding epigenetic mechanisms relevant to human diseases, focusing on the application of high-throughput genome technologies to characterize global DNA methylation profiles and more specifically, genomic imprinting. In particular, his studies have addressed the role of germline-derived monoallelic methylation in common cancers and specific developmental disorders with high incidence of childhood tumors.https://people.uea.ac.uk/d_monkD.Monk@uea.ac.uk
61
DrChrisMorrisSchool of PharmacyUEAExperimental peptide therapeutics and their activity in biological models. Current projects include: Phage display isolation of melanoma targeting peptides; SerpinA12 activity in malignant melanoma; Targeting autocrine growth signals (GRP) in small cell lung cancer; The use of phage display to identify DNA-binding and lectin-binding ligandshttps://people.uea.ac.uk/christopher_j_morrischristopher.j.morris@uea.ac.uk
62
ProfVincentMoultonSchool of Computing SciencesUEAPhylogenetics, computational biology of RNA, short RNAs, metatranscriptomics, algorithms in bioinformatics, and discrete structures such as graphs and finite metric spaces.https://people.uea.ac.uk/v_moultonv.moulton@uea.ac.uk
63
DrAnjaMuellerSchool of PharmacyUEAThe chemokine receptors CCR5 and CXCR4 act as a co-receptor for the HIV virus and together with other chemokine receptors, they have also been implicated in migration of cancerous cells. Our main interest lies in understanding the signal transduction induced by these receptors.https://people.uea.ac.uk/anja_muellerAnja.Mueller@uea.ac.uk
64
DrFelixNaughtonSchool of Health SciencesUEAThe development and evaluation of mobile phone interventions to promote and support health behaviour change, particularly those promoting smoking cessation, to prevent cancer and chronic disease. https://people.uea.ac.uk/f_naughtonf.naughton@uea.ac.uk
65
DrCaitlinNotleyNorwich Medical SchoolUEATobacco smoking relapse prevention, particularly targeting vulnerable populations. She has a particular interest in tobacco harm reduction approaches to treatment, and supporting maintenance of positive behaviour change for cancer prevention.https://people.uea.ac.uk/c_notleyc.notley@uea.ac.uk
66
ProfMariaO'ConnellSchool of PharmacyUEANatural products for the prevention and treatment of cancer. Novel therapeutics for cancer. https://people.uea.ac.uk/m_oconnellm.oconnell@uea.ac.uk
67
ProfSheinaOrbellDepartment of PsychologyEssexIntention-behaviour relation; Self-regulation; Social psychology of volition and volitional strategies in behavioural change; Motivational models of health-related behaviour; Social psychology of sexual health; Social-cognitive accounts of motivation and health-related behaviour; Cervical screening; Colorectal cancer screeninghttps://www.essex.ac.uk/people/orbel98203/sheina-orbellsorbell@essex.ac.uk
68
ProfAnneOsbournJohn Innes CentreNRPPlant natural products – biosynthesis, function, and mechanisms of metabolic diversification. Her discovery that the genes for many of these pathways are organized in plant genomes like ‘beads on a string’ has greatly accelerated the ability to find new pathways and chemistries of potential importance for the development of drugs (including anti-cancer agents) and other useful compoundshttps://www.jic.ac.uk/people/anne-osbourn/anne.osbourn@jic.ac.uk
69
DrMaría Paz MuñozSchool of ChemistryUEAUsing allenes as building blocks in their reaction with nucleophiles in the presence of (bi)metallic complexes towards the synthesis of natural product type molecules with potential biological activities. The biological activity of these complexes is currently being investigated as anticancer, antimicrobial and antifungal agents, as well as their interaction with imotif DNAhttps://people.uea.ac.uk/m_munoz-herranzm.munoz-herranz@uea.ac.uk
70
FilippoPrischiSchool of Life SciencesEssexThe characterisation of protein complexes that are part of signalling pathways, in normal and cancer cells.https://www.essex.ac.uk/people/prisc89105/filippo-prischifprischi@essex.ac.uk
71
ProfDmitryPshezhetskiyNorwich Medical SchoolUEAThe identification of molecular mechanisms of prostate cancer chemoresistance and metastasis and finding novel therapies to treat the disease.https://people.uea.ac.uk/d_pshezhetskiyd.Pshezhetskiy@uea.ac.uk
72
ProfDmitry PshezhetskiyNorwich Medical SchoolUEACancer molecular and cell biology and cancer therapies.https://people.uea.ac.uk/d_pshezhetskiyD.Pshezhetskiy@uea.ac.uk
73
DrShengQiSchool of PharmacyUEAWorks with patients, clinicians, regulatory bodies and medicine manufacturers to develop new commercially viable treatment solutions for unmet medical needs, particularly around personalised prevention, diagnostics and drug use. Current research includes nanocarrier-based targeted drug delivery technologies for treating colon and liver cancers, and personalised injectable and implantable delivery systems for treating solid tumours. https://people.uea.ac.uk/sheng_qiSheng.Qi@uea.ac.uk
74
DrCharalampos (Babis) RallisSchool of Life SciencesEssexApproaches in fission yeast and 2D/3D human tissue culture systems (fibroblasts, neural stem cells and neuroblastoma-derived human neurons) to investigate the molecular basis of cellular fitness, cancer and ageing with a focus on the nutrient-responsive signalling pathway Target of Rapamycin (TOR). https://www.essex.ac.uk/people/ralli86406/charalampos-babis-rallisc.rallis@essex.ac.uk
75
DrStephenRobinsonQuadram InstituteNRPCell Signalling and Angiogenesishttps://people.uea.ac.uk/stephen_robinsonstephen.robinson@uea.ac.uk
76
DrStuart RushworthNorwich Medical SchoolUEAThe function of the tumour microenvironment in the malignant bone marrow. Using this knowledge we also study the physiology of haematopoietic stem cells in response to infection.https://people.uea.ac.uk/s_rushworths.rushworth@uea.ac.uk
77
DrAramSaeedSchool of PharmacyUEAExpertise span across several disciplines including polymer science (Chemistry), pharmaceutical formulation (Pharmacy), and tissue engineering and regenerative medicine (Biology and Medicine). Work includes targeted therapeutics for cancer treatment with “Smart” nanomaterial with controlled-release featureshttps://people.uea.ac.uk/aram_saeedaram.saeed@uea.ac.uk
78
ProfMarkSearceySchool of PharmacyUEAThe targeting of DNA as a potential route to therapeutically useful molecules.https://people.uea.ac.uk/m_searceym.searcey@uea.ac.uk
79
DrAnastasiaSobolewskiSchool of PharmacyUEAUnderstanding the mucosal environment of the lung and gut during health, inflammation and cancer. In particular, we investigate how gut and lung epithelial stem cells are modulated by the inflammatory and tumour microenvironment.https://people.uea.ac.uk/a_sobolewskiA.Sobolewski@uea.ac.uk
80
DrEwenSpeedSchool of Health and Social CareEssexHealth policy, particularly in the context of the NHS; critical approaches to understanding engagement and involvement in healthcare, and to psychology and psychiatry.https://www.essex.ac.uk/people/speed44207/ewen-speedesspeed@essex.ac.uk
81
ProfG. Richard StephensonSchool of ChemistryUEASynthetic organic chemistry and methodologies for enantioselective synthesis. Our targets are functional molecules with a variety of applications including functionalised calix[n]arenes and multi-cavitands as novel receptors and switchable NLOphores, helicenes for use in Two Photon Circular Dichroism (TPCD), bioactive compounds targeting neglected tropical diseases (NTDs) and as potential anti-cancer leads by the inhibition of ubiquitin ligase, and novel reagents for cellulose derivatisation for biocomposite applications.https://people.uea.ac.uk/g_r_stephensong.r.stephenson@uea.ac.uk
82
DrVadimSumbayevMedway School of PharmacyKentThe mechanisms of adaptation of human hematopoietic cells of myeloid lineage to different types of stress associated with low oxygen availability. Based on the group's understanding of these mechanisms and recent advances in Nanotechnology they are trying to apply gold nanoparticle-based Synthetic Biology approaches to specifically target HIF-1 transcription complex and associated pathways in human myeloid hematopoietic cells. This could allow pharmacological correction of pathophysiological reactions of these cells in cases of autoimmune disorders, allergic reactions and leukaemia progression.https://msp.ac.uk/person/vadim-sumbayev/v.sumbayev@kent.ac.uk
83
ProfAnn MarieSwartNorwich Medical SchoolUEAThe design, conduct and analysis of practice changing clinical trials in a wide range of therapeutic areas and novel treatments, particularly involving academic/industry collaborations. Includes work on ovarian cancer.https://people.uea.ac.uk/a_swarta.swart@uea.ac.uk
84
ProfAnne MarieSwartNorwich Medical SchoolUEAThe design, conduct and analysis of practice changing clinical trials in a wide range of therapeutic areas and novel treatments, particularly involving academic/industry collaborations. Recently completed projects:ICON7 Bevacizumab in the first line treatment of ovarian cancer; ICON6 (Co-CI) Cediranib in relapsed ovarian cancer; Chorus (Co-CI) Neoadjuvant chemotherapy for advanced ovarian cancerhttps://people.uea.ac.uk/a_swartA.Swart@uea.ac.uk
85
DrVladimirTeifSchool of Life SciencesEssexCancer epigenetics; Modelling gene regulation in chromatin; Computational modelling of cell differentiation; Nucleosome positioning; Transcription factor-focused description of gene regulationhttps://www.essex.ac.uk/people/teifv75808/vladimir-teifvteif@essex.ac.uk
86
DrMariaTrakaQuadram InstituteNRPDeputy Head of Food Databanks National Capability, which curates and manages the food composition data of the UK diets. I have an active interest in personalized nutrition, prevention of Non Communicable Diseases, and the importance of the microbiome in modulating response to complex diets. Previous work has included looking at the molecular mechanisms leading to disease prevention (e.g. prostate cancer).https://quadram.ac.uk/people/maria-traka/maria.traka@quadram.ac.uk
87
DrJenniferTulletSchool of BiosciencesKentAgeing biology, transcriptional regulation and C. elegans geneticshttps://www.kent.ac.uk/biosciences/people/1027/tullet-jenniferj.m.a.tullet@kent.ac.uk
88
DrDavidTurnerNorwich Medical SchoolUEAThe conduct of economic evaluations alongside randomised controlled trials and other clinical studies. Has included Raman spectral imaging for automated Mohs Micrographic surgery of high-risk Basal Cell Carcinoma.https://people.uea.ac.uk/david_a_turnerdavid.a.turner@uea.ac.uk
89
DrZoeWallerSchool of PharmacyUEADrug-nucleic acid interactions and studying alternative DNA structures. Her research has two general themes: switching DNA conformation for uses in nanotechnology and targeting DNA/RNA with small molecule ligands for applications in biology. The work has applications in nanotechnology, chemical biology and development of novel therapeutics for genetic diseases such as cancer, diabetes or fragile X syndrome.https://people.uea.ac.uk/z_wallerZ.Waller@uea.ac.uk
90
DrMarkWassSchool of BiosciencesKentTwo main areas: The first is the development of novel computational methods for the analysis of large scale biological data, particularly methods for the prediction of protein structure, function and interactions. The second area is the application of such methods to address important biological problems. These cover the association of genetic variation with human disease, investigating mechanisms and biomarkers of acquired resistance to anti-cancer drugs and also identifying determinants of pathogenicity in viruses. https://www.kent.ac.uk/biosciences/people/1137/wass-markm.n.wass@kent.ac.uk
91
ProfGrantWheelerSchool of Biological SciencesUEAThe molecular events that govern the origin and migration of different cell types within the developing embryo. The model organism we use is the amphibian, Xenopus. The main cell type the lab focusses on is the Neural Crest. Cancers that develop from neural crest derived tissues are pheocytochromas, neuroblastomas and melanoma. The Wheeler lab is particularly interested in melanoma and its similarities to the Neural Crest.https://people.uea.ac.uk/grant_wheelerGrant.Wheeler@uea.ac.uk
92
ProfJenniferWhittyNorwich Medical SchoolUEAEvaluating patient and public preferences, choices and values around health outcomes and services.https://people.uea.ac.uk/jennifer_whittyjennifer.whitty@uea.ac.uk
93
DrMarkWilliamsSchool of Biological SciencesUEAHow age-related molecular damage and inherited genetic defects pre-dispose the intestinal epithelium to the onset of gastrointestinal disease.https://people.uea.ac.uk/m_r_williamsm.r.williams@uea.ac.uk
94
DrRalphZwackaSchool of Life SciencesEssexMesenchymal stem cells and cancer therapy; Apoptosis pathways and treatment resistance mechansims in cancer; Cell death regulation in stem cells; Redox-regulated pathways in cancer and stem cellshttps://www.essex.ac.uk/people/zwack67603/ralf-zwackarzwacka@essex.ac.uk
95
96
97
98
99
100